EP0489733A1 - Antibakterielles pyrido(1,2,3-de)-1,4-benzoxazinon-mittel - Google Patents

Antibakterielles pyrido(1,2,3-de)-1,4-benzoxazinon-mittel

Info

Publication number
EP0489733A1
EP0489733A1 EP90906002A EP90906002A EP0489733A1 EP 0489733 A1 EP0489733 A1 EP 0489733A1 EP 90906002 A EP90906002 A EP 90906002A EP 90906002 A EP90906002 A EP 90906002A EP 0489733 A1 EP0489733 A1 EP 0489733A1
Authority
EP
European Patent Office
Prior art keywords
compound
hydrogen
methyl
pyrido
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90906002A
Other languages
English (en)
French (fr)
Inventor
Sharon N. Bisaha
Ronald B. Gammill
Thomas M. Judge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of EP0489733A1 publication Critical patent/EP0489733A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to new 2-[4-[6-carboxy-9-fluoro- 2,3-dihydro-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazin-10-yl]diaminyl]- 2-butendioic acid, 1,4 disubstituted esters useful as antibacterial agents.
  • Ofloxacin and various analogs are known for their antibacterial properties, however new antibacterials are continually sought especially those which exhibit both gram positive and gram negative activity.
  • U.S. Patent 4,777,253 discloses various methods of producing the racemate and enantiomers of 9-fluoro-3-methyl-10-substituted amino-7- oxo-2,3-dihydro-7H-pyrido[l,2,3-de]-1,4-benzoxazine-6-carboxylic acid compounds.
  • the present invention is directed toward new compounds useful as antibacterials or in the preparation of antibacterial compositions.
  • the compound of the present invention is as shown in Formula I or therapeutically acceptable salts wherein:
  • R 1 is hydrogen or hydroxyl
  • R 2 is hydrogen or methyl
  • R 3 is hydrogen, halogen, amine or hydroxyl
  • R 4 , R 5 , R 6 , R 7 are independently hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, ethenyl, ethynyl, C 3 -C 6 cycloalkyl, fluoromethyl, difluoromethyl, difluoroethyl, trifluoromethyl, hydroxymethyl, C 1 - C 18 alkoxy methyl, phenoxymethyl, C 1 -C 3 alkyl aminomethyl, C 1 -C 3 dialkyl aminomethyl, C 6 -C 12 aryl, substituted aryl, heteroaryl or substituted heteroaryl containing at least one O, N or S;
  • R 8 Is hydrogen, hydroxyl, amine, C 1 -C 4 alkoxy or aryloxy, -SH, C 1 -C 6 thioalkyl or thioaryl;
  • R 9 is C 1 -C 4 alkyl, C 6 -C 12 aryl, alkylaryl, heteroaryl, -(CH 2 ) n - CO 2 -(CH 2 ) m -R 11 , wherein R 11 is hydrogen, hydroxyl, methyl, alkyloxy, aryloxy or an amine, n is 0-4 and m is 0-4;
  • R 10 is hydrogen, -(CH 3 ) o, C 2 -C 4 alkyl, C 6 -C 12 aryl, alkylaryl, heteroaryl, or acetyl, where o is 0 or 1;
  • R 12 is hydrogen CN, halogen, or R 9 ;
  • Z is (CH 2 ) q where q is 0-2, CH-CH 3 or C(CH 3 ) 2 .
  • R 10 is -(CH 3 ) o where o is 0 and preferably, Z is (CH 2 ) q where q is 0.
  • Preferred compounds of the present invention include (E)-2-[4- [6-carboxy-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)- 1,4-benzoxazin-10-yl]-1-piperazinyl]-2-butendioic acid, 1,4-dimethyl ester (Compounds 1) and (E)-2-[4-[6-carboxyethyl-9-fluoro-2,3- dihydro-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazin-10-yl]-1- piperazinyl]-2-butendioic acid, 1,4-dimethyl ester (Compound 2).
  • the present invention is a pharmaceutical composition containing an antibacterially effective amount of a compound or therapeutically acceptable salts thereof according to Formula I in admixture with a pharmaceutical carrier.
  • the composition can contain from about 0.5 to about 90% by weight of such compound.
  • the composition can be present in unit dose form of tablets, pills, dragees, capsules, ampules or suppositories.
  • the present invention is method for treating bacterial infection in animals including humans which comprises administering an antibacterially effective amount of a compound or therapeutically acceptable salts thereof according to Formula I.
  • the compound can be administered orally or parenterally.
  • the presenf. invention relates to pyrido(1,2,3-de)-1,4- benzoxazinone carboxylic acids incorporating a novel 1,2-dicar- boxyethylene substitutent and antibacterial agents containing these compounds.
  • the benzoxazinone compounds are structurally represented by Formula I, shown on the Formula Sheet, and includes therapeutically acceptable salts thereof wherein R 1 is hydrogen or hydroxyl; R 2 is hydrogen or methyl; R 3 is hydrogen, halogen, amine or hydroxyl; R 4 , R 5 , R 6 , R 7 are independently hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, ethenyl, ethynyl, C 3 -C 6 cycloalkyl, fluoromethyl, difluoro- methyl, difluoroethyl, trifluoromethyl, hydroxymethyl, C 1 -C 18 alkoxy methyl, phenoxy-methyl, C 1 -C 3 alkyl aminomethyl, C
  • R 10 is -(CH 3 ) o where o is
  • Z is (CH 2 ) q where q is 0.
  • Preferred compounds of Formula la are where R 1 is hydroxy, R 2 is hydrogen or methyl, R 3 is hydrogen or fluorine, R 4 , R 5 , R 6 and R 7 are hydrogen, R 8 is methoxyl, R 9 is a carbomethoxyl ester so as to form either the dimethylester of maleic or fumaric acid and R 10 is- (CH 3 ) o where o is 0.
  • Preferred compounds of Formula lb are when R 1 is hydroxyl and R 2 is hydrogen or methyl and R 11 are hydrogen, R 8 is O-CH 3 , R 9 is C(O)OCH 3 , X and Y are C(F) and Z is (CH 2 ) q where q is zero.
  • C 1 -C 10 alkyl are one to ten carbon atoms such as methyl, ethyl, propyl, butyl, etc. and isomeric forms thereof.
  • the "C 2 -C 4 alkylenes” are ethylene, propylene and 1 or 2-butylene and isomeric forms thereof.
  • Examples of "C 3 -C 10 cycloalkyl” are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. and "heterocycloalkyl”are cycloalkyl ring which contain at least one heteroatom such as oxygen, sulfur or nitrogen.
  • C 6- C 12 aryl are compounds such as phenyl, ⁇ -naphfchyl, ⁇ -naphthyl, m-methylphenyl, p-trifluoromethyIphenyl and the like.
  • the aryl groups can also be substituted with one to 3 hydroxy, C 1 -C 3 alkoxy, C 1 -C 3 alkyl, trifluoromethyl, fluoro, chloro or bromo groups.
  • alkylaryl are alkyl chains of one to eight carbon atoms and isomeric forms thereof which are substituted with aryl groups of 6 to 12 carbon atoms, for example, benzyl.
  • heteroaryls are 6 to 12 carbon atom aryls which contain at least one heteroatom such as nitrogen, sulfur and oxygen.
  • amine is meant to Include primary, secondary and tertiary amines , preferably primary amine (NH 2 ).
  • Halogen is meant to include F, Cl, Br and I.
  • “Therapeutically acceptable salts” are those compounds of Formula I wherein a carboxyl group is substituted with a counter ion such as Li, Na, K, Ca or other acceptable counter ions for carboxylic acids .
  • the compounds according to the invention have good actions against Gram-positive and Gram-negative bacteria, particularly against enterobacteriaceae.
  • the effectiveness of the subject compounds on bacteria were obtained by performing a dip disk assay.
  • the antibacterial activity of the compounds was determined by the disk-diffusion method. Paper disks (12.7 mm) were loaded with 0.05 ml of drug solution prepared at a concentration of 0.1 mcg/ml; the disks were allowed to air dry.
  • microorganism-seeded agar assay trays which contained the bacterial strain Pseudomonas aeruginosa UC 95 (PA), Escherichia coli UC 51 (EC), Klebsiella pneumoniae UC 57 (KP), Staphylococcus aureus UC 80 (SA), Penicillium oxalicum UC 1268 (PO), Streptococcus pyogenes UC 6055 (ST), Bacteroides fragilis UC 6513 (BF), Candida albicans UC 1392 (CA),
  • PA bacterial strain Pseudomonas aeruginosa UC 95
  • EC Escherichia coli UC 51
  • KP Klebsiella pneumoniae UC 57
  • SA Staphylococcus aureus UC 80
  • PO Penicillium oxalicum UC 1268
  • ST Bacteroides fragilis UC 6513
  • Staphylococcus aureus UC 6685 SR
  • Staphylococcus epidermidis UC 719 SE
  • Streptococcus pneumoniae UC 9207 SO
  • UC 241 (SF), Serratica marcescens UC 6888 (SM), Bordetella bronchiseptica UC 6481 (BR) or Clostridium perfringens UC 6509 (CP).
  • SF Serratica marcescens UC 6888
  • BR Bordetella bronchiseptica UC 6481
  • CP Clostridium perfringens UC 6509
  • MIC minimum inhibitory concentration
  • McFarland standard Is obtained.
  • the bacteria are diluted one to 20 in TSB and inoculated on the plates (1 ⁇ l using a Steers replicator).
  • the plates are incubated at 35°C for 20 hours and the MIC is read to be the lowest concentration of drug that completely inhibits visible growth of the bacteria.
  • the MIC test results of selected compounds of this invention are found in Tables I.
  • the compounds according to the invention have a potent and broad antimicrobial efficacy. These properties make it possible to use them as chemotherapeutic active compounds in medicine and as substances fpr preserving inorganic and organic materials, in particular organic materials of all types, for example polymers, lubricants, dyes, fibers, leather, paper and wood, foodstuffs and water.
  • the compounds according to the invention are active against Gram-negative and Gram-positive bacteria and bacterioid microorganisms. Thus, diseases caused by these pathogens can be treated.
  • the compounds according to the invention are particularly active against bacteria and bacterioid microorganisms. Thus, they are particularly well suited for the chemotherapy of local and systemic infections caused by these pathogens in medicine.
  • Micrococcaceae such as staphylococci, for example Staphylococcus aureua, Staph. Epidermidis, (Staph.
  • Lactobacteriaceae such as streptococci, for example Streptococcus pyogenes, ⁇ - and ⁇ -haemolytic streptococci, non ( ⁇ -) haemolytic streptococci, enterococci and Dlplococcus pneumoniae (pneumococci) (Str - Streptococcus); Enterobacteriaceae, such as encherichiae bacteria of the coli group; encherichia bacteria, for example Escherichia coli, enterobacter bacteria, for example aerogenes, E. cloacae, Klebsiella bacteria, for example K.
  • streptococci for example Streptococcus pyogenes, ⁇ - and ⁇ -haemolytic streptococci, non ( ⁇ -) haemolytic streptococci, enterococci and Dlplococcus pneumoniae (pneumococci) (Str - Streptoc
  • pneumoniae serratin, for example Serratia marcescens (E. - Enterobacter) (K. - Klebsiella), proteae bacteria of the proteus groups; proteus, for example Proteus vulgaris, Pr. morganii, Pr. rettgeri and Pr. mirabilis (Pr. - Proteus); pseudomonadaceae, such as pseudomonas bacteria, for example Pseudomonas aeruginosa (PS. - Pseudomonas); bacteroidaceae, such as bacteroides bacteria, for example Bacteroides fragilis (B. - Bacteroides); mycoplasma, for example Mycoplasma pneumonia.
  • serratin for example Serratia marcescens (E. - Enterobacter) (K. - Klebsiella), proteae bacteria of the proteus groups; proteus, for example Proteus vulgaris, Pr. morganii, Pr. rettgeri
  • the present invention includes pharmaceutical preparations which in addition to non-toxic, inert pharmaceutically suitable excepients contain one or more compounds according to the invention or which consist of one or more active compounds according to the invention, and processes for the production of these preparations.
  • the present invention also Includes pharmaceutical preparations in dosage units.
  • the preparations are in the form of individual parts, for example tablets, dragees, capsules, pills, suppositories and ampoules, of which the content of active substance corresponds to a fraction or a multiple of an individual dose.
  • An individual dose preferably contains the amount of active compound which is given in one administration and which usually corresponds to a whole, a half or a third or a quarter of a daily dose.
  • non-toxic, inert pharmaceutically suitable excipients there are solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.
  • Preferred pharmaceutical preparations are tablets, dragees, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays.
  • Tablets, dragees, capsules, pills and granules can contain the active compound or compounds alongside the customary excipients such as (a) fillers and extenders, for example starches, lactose, sucrose, glucose, mannitol and silica, (b) binders, for example carboxymethylcellulose, alginates, gelatine and polyvinylpyrrolidone, (c) humectants, for example glycerine, (d) disintegrating agents, for example agar-agar, calcium carbonate and sodium carbonate, (e) solution retarders, for example paraffin, and (f) absorption accelerators, for example quaternary ammonium compound (g) wetting agents, for example cetyl alcohol or glycerine monostearate, (h) adsorbents, for example kaolin and bentonite, and (i) lubricants, for example talc, calcium stearate and magnesium stearate and solid polyethylene glycols, or
  • the tablets, dragees, capsules, pills and granules can be provided with the customary coatings and shells, optionally containing opacifying agents, and can also be of such composition that they release the active compound or compounds only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner, examples of embedding compositions which can be used being polymeric substances and waxes.
  • the active compound or compounds can also be in a micro- encapsulated form.
  • Suppositories can contain, in addition to the active compound or compounds, the customary water-soluble or water-insoluble excipients, for example polyethylene glycols, fats, for example cacao fat, and higher esters (for example C 14 -alcohol with C 16 -fatty acid) or mixtures of these substances.
  • the customary water-soluble or water-insoluble excipients for example polyethylene glycols, fats, for example cacao fat, and higher esters (for example C 14 -alcohol with C 16 -fatty acid) or mixtures of these substances.
  • Ointments, pastes, creams and gels can contain the customary excipients in addition to the active compound or compounds, for example animal and vegetable fats, waxes, paraffins, starch, traga- canth, cellulose derivatives, polyethylene glycols, silicones, ben- tonites, silica, talc and zinc oxide or mixtures of these substances.
  • Powders and sprays can contain the customary excipients in addition to the active compound or compounds, for example lactose, talc, silica, aluminum hydroxide, calcium silicate and polyamide powders or mixtures of these substances.
  • Sprays can additionally contain the customary propellents, for example chlorofluorohydro- carbons.
  • Solutions and emulsions can contain the customary excipients in addition to the active compound or compounds, such as solvents, solubilising agents and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, especially cottonseed oil, groundnut oil, maize germ oil, olive oil, castor oil and sesame oil, glycerine, glycerineformal, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances.
  • solvents such as solvents, solubilising agents and emulsifiers
  • solubilising agents and emulsifiers for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, e
  • the solutions and emulsions can be in a sterile form which is isotonic with blood.
  • Suspensions can contain the customary excipients in addition to the active compound or compounds, such as liquid diluents, for example water, ethyl alcohol or propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.
  • liquid diluents for example water, ethyl alcohol or propylene glycol
  • suspending agents for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.
  • the formulation forms mentioned can also contain dyestuffs, preservatives and additives which improve the odour and flavour, for example peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.
  • the therapeutically active compounds should preferably be present in the above mentioned pharmaceutical preparations in a concentration of about 0.1 to 99.5, preferably of about 0.5 to 95, percent by weight of the total mixture.
  • compositions can also contain other pharmaceutical active compounds in addition to the active compounds according to the invention.
  • compositions are manufactured in the usual manner according to known methods, such as by mixing the active compound or compounds with the excipient or excipients.
  • the active compounds or the pharmaceutical preparations can be administered locally, orally, parenterally, intraperitoneally and/or rectally, preferably orally or parenterally, such as intravenously or intramuscularly.
  • the active compound or compounds in total amounts of about 0.5 to about 50, preferably 1 to 30, especially preferably 1-20 mg/kg of body weight, orally or parenterally, every 24 hours, optionally in the form of several individual administrations, in order to achieve the desired results.
  • An individual administration contains the active compound or the active compounds preferably in amounts of about 1 to about 250, especially of 3 to 60, mg/kg of body weight.
  • the compounds of Formula I according to this invention may be provided as pharmaceutically acceptable acid addition and base salts wherein the anion or cation, respectively, does not contribute significantly to the toxicity of the salt and which salts are compatible with the standard and conventional pharmaceutically acceptable carriers and other conventional adjuvants and excipients customarily employed in producing pharmaceutical compositions adapted for oral or parenteral administration.
  • the acid addition salts are formed by conventional techniques involving reaction of compounds of Formula I with mineral acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, and sulfuric acid, and with organic carboxylic and sulfonic acids such as, for example, aspartic acid, glutamic acid, galaeturonic acid, gluconic acid, acetic acid, citric acid, maleic acid, succinic acid, benzoic acid, tartaric acid, ascorbic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, and the like.
  • mineral acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, and sulfuric acid
  • organic carboxylic and sulfonic acids such as, for example, aspartic acid, glutamic acid, galaeturonic acid, gluconic acid, acetic acid, citric acid, maleic
  • this invention is a pharmaceutical composition comprising an antibacterially effective amount of a compound of Formula I above.
  • this invention is a method of combatting hacterial Infection in warm-blooded animals comprising administering to said animals an antibacterially effective amount of a compound of Formula I err of a pharmaceutical composition thereof.
  • Pharmaceutically acceptable base salts are formed by conventional techniques involving reaction of the compounds of Formula I with alkali (Na,K) and alkaline earth (Ca, Ba, Zn, Mn) metal bases, more preferably with alkali metal bases such as, for example, dilute solutions of sodium hydroxide and potassium carbonate.
  • pharmaceutically acceptable base salts are formed by conventional techniques involving reaction with amines such as, for example, triethyl- amine, dibenzylamine, triethanolamine, ethanolamine, N,N'-dibenzyl- ethylenediamine, procaine and equivalent amines.
  • the new compounds can be utilized as feedstuff.
  • Dimethyl acetylene dicarboxylate (55 ⁇ L, 0.45 mmol) is added to a stirring solution of 9-fluoro-3-methyl-10-(1-piperazinyl)-7-oxo- 2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (0.15 g, 0.45 mmol) in dimethyl formamide (5 ml, DMF).
  • the solution is stirred at room temperature for 8 hours, the solvent evaporated off under a stream of nitrogen.
  • the residue is flash chromatographed over silica gel (15 g, 0.5% acetone in 10% methanol/methylene chloride) to yield 0.13 g of Compound #1 (m.p. 235-238oC).
  • Hayakawa et al. and can be prepared in accordance with Procedure 2.
  • Dimethyl acetyl dicarboxylate (0.19 ml, 1.5 mol) is added to a stirring solution of 9-fluoro-3-methyl-10-(3-amino-1-pyrrolidinyl)-7- oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (0.52 g, 1.5 mmol) in dimethylformamide (13 ml).
  • the solution is stirred at room temperature for 3 days, the solvent evaporated off under a stream of nitrogen.
  • Triethylorthoformate (15.8 g, 106 mmol) is added to a solution of ⁇ , ⁇ -DIoxo-2,3,4,5.-tetrafluoro-benzenebutanoic acid, ethyl ester (50 g, 0.19 mmol) in acetic anhydride (80ml). After refluxing for 5 hours, the solvent is evaporated and azeotroped with toluene twice in vacuo at 60°C to yield 67 g of 2,3,4,5-tetrafluoro- ⁇ -[(ethoxy)- methylene]- ⁇ -oxo-benzenepropanoic acid, ethyl ester. The product is stored at -20°C and can be use in subsequent steps without further purificiation.
  • D,L-Alanol (2.34 g, 31.2 mmol) is added to a solution of 2,3,4,5-tetrafluoro- ⁇ -[(ethoxy)methylene]- ⁇ -oxo-benzenepro ⁇ anoic acid, ethyl ester (10.0 g, 31.2 mmol of Part A) in methylene chloride (50 ml).
  • Piperazine (0.9 g, 10.5 mmol) is added to a solution of the difluoro acid 9,10-difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(- 1,2,3-de)-1,4-benzoxazine-6-carboxylic acid (0.75 g, 2.67 mmol) in DMSO (15 ml). After stirring at 120°C for 3 h, the solvent is evaporated in vacuo at 60°C. The residue is washed with cold water to afford 0.42 g of crude product.
  • 3-Acetoaminopyrrolidine (3.84 g, 30 mmol) is added to a solution of the difluOro ester (4.65 g, 15 mmol, Procedure 1, Part C) in pyridijie (55 ml). After stirring at 60"C for 6 days, the solvent is evaporated in vacuo at 60"C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP90906002A 1989-04-26 1990-01-22 Antibakterielles pyrido(1,2,3-de)-1,4-benzoxazinon-mittel Withdrawn EP0489733A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34388089A 1989-04-26 1989-04-26
US343880 1989-04-26

Publications (1)

Publication Number Publication Date
EP0489733A1 true EP0489733A1 (de) 1992-06-17

Family

ID=23348083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90906002A Withdrawn EP0489733A1 (de) 1989-04-26 1990-01-22 Antibakterielles pyrido(1,2,3-de)-1,4-benzoxazinon-mittel

Country Status (4)

Country Link
EP (1) EP0489733A1 (de)
JP (1) JPH04504852A (de)
AU (1) AU5404790A (de)
WO (1) WO1990012799A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
US5696117A (en) * 1995-11-07 1997-12-09 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
KR100309871B1 (ko) 1999-02-24 2001-10-29 윤종용 (-)피리도벤즈옥사진 카르복실산 유도체의 제조방법
KR100542600B1 (ko) * 2004-05-17 2006-01-11 주식회사 카이로켐 광학활성 (s)-피리도벤즈옥사진 카르복실산 반수화물 유도체의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3543513A1 (de) * 1985-12-10 1987-06-11 Bayer Ag Enantiomerenreine 1,8-verbrueckte 4-chinolon-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel und ihre verwendung zur herstellung von arzneimitteln
DE3711193A1 (de) * 1987-04-02 1988-10-13 Bayer Ag 5-substituierte chinolon- und naphthyridoncarbonsaeure-derivate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9012799A1 *

Also Published As

Publication number Publication date
AU5404790A (en) 1990-11-16
JPH04504852A (ja) 1992-08-27
WO1990012799A1 (en) 1990-11-01

Similar Documents

Publication Publication Date Title
KR910006806B1 (ko) 퀴놀린 유도체의 제조방법
US4880806A (en) 1-Cyclopropyl-6-fluoro-7-piperazinyl-1,4-Dihydro-4-oxo-quinoline-3-carboxylic acid derivatives
EP0198192B1 (de) 7-Amino-1-(subst.cyclopropyl)-1,4-dihydro-4-oxo-3-chinolincarbonsäuren, Verfahren zu ihrer Herstellung sowie diese enthaltende antibakterielle Mittel
DK172077B1 (da) 6-Fluor-7-(4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinolin-3-carboxylsyre-derivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende disse forbindelser
HK62191A (en) A 6-fluoro-1,4-dihydro-4-oxo-7-substituted piperazinyl-quinoline-3-carboxylic acid derivative and the method for preparing the same
IL124337A (en) Pyrido-oxazine derivatives, pharmaceutical preparations containing them and a method for their preparation
EP0266576A2 (de) 1-Tert-alkyl-substituierte Naphthyridin- und Chinolincarbonsäure als antibakterielle Mittel
HU199821B (en) Process for production of derivatives of in 8 position substituated quinoline carbonic acid and medical compositions containing them
KR910006635B1 (ko) 1,7-디아미노-1,4-디하이드로-4-옥소-3-(아자)퀴놀린카복실산의 제조방법
HU187449B (en) Process for producing new quiniline-carboxylic acid derivatives and pharmaceutical compositions containing them as active agents
EP0109284B1 (de) 6,7-Dihydro-5,8-dimethyl-9-fluor-1-oxo-1H,5H-benzo(ij)chinolizin-2-carbonsäure und ihre Derivate
US5385906A (en) Antibacterial quinolone compounds
EP0387802A2 (de) 5-Substituierte 1,4-Dihydro-4-oxonaphthyridin-3-carbonsäure als antibakterielles Mittel
JPH03151384A (ja) 新規なベンゾ〔ｂ〕〔１，８〕ナフチリジン誘導体、その製造及びそれを含む組成物
EP0447484A1 (de) Antibakterielle chinolonverbindungen
EP0312085B1 (de) Chinolinderivate, Verfahren zur Herstellung davon und diese enthaltendes antibakterielles Mittel
EP0109285A1 (de) 6,7-Dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo(ij)chinolizin-2-carbonsäuren und deren Derivate
EP0191390B1 (de) 1-Cyclopropyl-1,4-dihydro-4-oxo-7-[4-(2-oxo-1,3-dioxol-4-yl-methyl)-1-piperazinyl]-3-chinolincarbonsäuren, Verfahren zu ihrer Herstellung sowie diese enthaltende antibakterielle Mittel
EP0489733A1 (de) Antibakterielles pyrido(1,2,3-de)-1,4-benzoxazinon-mittel
EP0207497A2 (de) Chinoloncarbonsäurederivat und Verfahren zu seiner Herstellung
EP0286089B1 (de) Chinolincarbonsäure-Derivate, diese enthaltende Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Medikamenten
EP0306860A2 (de) 4-Oxo-3-chinolincarbonsäure, verwendbar als bakterizide Mittel und ihre Herstellung
US4439436A (en) 1,3-Dioxolo(4,5-G)quinoline compounds
EP0319906A2 (de) Chinolinderivate, Verfahren zu ihrer Herstellung und sie enthaltendes antibakterielles Mittel
US4720495A (en) Benzo[ij]quinolizine-2-carboxylic acids useful for treating bacterial infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19911121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19930805